Search Results 1401-1410 of 19188 for Neutrophil

1. A Study to Evaluate the Safety and Effectiveness of IFX-1 in Add-on to Standard of Care in Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) - Mayo Clinic

   History of positive antigen-specific anti-neutrophil cytoplasmic antibody (ANCA) test through a documented positive ELISA test for either anti-proteinase 3 ...

2. Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer - Mayo Clinic

   Absolute neutrophil count ≥ 1,500/mcL (within 28 days prior to administration of study treatment). Platelets ≥ 100,000/mcL (within 28 days prior to ...

3. Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma - Mayo Clinic

   Abbreviations: ALT = alanine aminotransferase; ANC = absolute neutrophil count; AST = aspartate aminotransferase; BM = bone marrow; INR = international ...

4. A Study to Evaluate Dabrafenib and Trametinib With or Without Hydroxychloroquine in Advanced Melanoma - Mayo Clinic

   Absolute neutrophil count ≥ 1,500/mcL (obtained ≤ 14 days prior to protocol randomization). Platelets ≥ 100,000/mcL (obtained ≤ 14 days prior to ...

5. https://www.mayoclinic.org/chinese_organization_concepts.xml

6. Testing Nivolumab and Ipilimumab With Short-Course Radiation in Advanced Rectal Cancer - Mayo Clinic

   Absolute neutrophil count (ANC) ≥ 1,500/mcL (must be obtained ≤ 14 days prior to protocol registration). Platelets ≥ 100,000/mcL (must be obtained ≤ 14 ...

7. Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors - Mayo Clinic

   Absolute neutrophil count (ANC) ≥ 1,000/mm³ (> 250/mm³ for patients with neuroblastoma); Platelet count ≥ 75,000/mm³ (> 25,000/mm³ for patients with ...

8. Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma - Mayo Clinic

   Obtained =< 14 days prior to registration: Absolute neutrophil count (ANC) >= 1000/uL (without growth factor support); Obtained =< 14 days prior to ...

9. Phase III Study Of Datopotamab Deruxtecan Versus Docetaxel In Previously Treated TROP2-positive Advanced Non-squamous NSCLC Without AGA - Mayo Clinic

   Absolute neutrophil count ≥ 1.5 × 109 /L (granulocyte colony stimulating factor administration is not allowed within 1 week prior to screening assessment).

10. A Study to Evaluate the Safety and Effectiveness of Crinecerfont in Adults with Classic Congenital Adrenal Hyperplasia - Mayo Clinic

    Absolute neutrophil count < 1.0 × 103 /mm^3. Have any of the following abnormal coagulation abnormalities at screening: Activated partial thromboplastin ...